13/2 (NE) Dmr 4-25-02

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

Bringhurst et al.

Appl. No. 09/448,867

Filed: November 24, 1999

For: Modified Human Parathyroid

Hormone (As Amended)

Confirmation No.: 5545

Art Unit: 1647

Examiner: Wegert, S.L.

Atty. Docket: 0609.4640001/SRL/M-G



Amendment Under 37 C.F.R. § 1.312

Attn: Box Issue Fee

Commissioner for Patents Washington, D.C. 20231

Sir:

Submitted herein is an Amendment Under 37 C.F.R. § 1.312. As payment of the issue fee has not yet been made, Applicants respectfully submit that filing under 37 C.F.R. § 1.312 is proper. (M.P.E.P. § 714.16.)

It is believed that extensions of time are not required beyond those that may otherwise be provided for in documents accompanying this Amendment. However, if additional extensions of time are necessary to prevent abandonment of this application, then such extensions of time are hereby petitioned under 37 C.F.R. § 1.136(a), and any fees required therefor are hereby authorized to be charged to our Deposit Account No. 19-0036.

This Amendment is provided in the following format:

- (A) A clean version of each replacement paragraph/section/claim along with clear instructions for entry;
- (B) Starting on a separate page, appropriate remarks and arguments. 37 C.F.R. § 1.111 and MPEP 714; and
- (C) Starting on a separate page, a marked-up version entitled: "Version with markings to show changes made."